Compare Abbott Laboratories (ABT) vs Cintas Corporation (CTAS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Cintas Corporation — how do they compare? Abbott Laboratories trades at $95.59 (market cap $166.94B), while Cintas Corporation trades at $181.96 (market cap $72.76B). The key difference: Abbott Laboratories is far larger — about 2.3× Cintas Corporation's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | CTAS | |
|---|---|---|
Market Cap | $166.94B | $72.76B |
Sector | Health | Industrials |
52-Week High | $136.62 | $226.27 |
52-Week Low | $82.57 | $163.55 |
Enterprise Value | $193.69B | $75.49B |
Dividend Yield | 2.63% | 0.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
CTAS trades at $181.83, up 0.29% with a bullish technical signal. The stock shows strong fundamentals with revenue growing from $7.9B in 2022 to $10.3B in 2025 and net income margins expanding to 17.57%. Recent earnings mostly beat expectations, and the company maintains a 43-year dividend growth streak. Positive sentiment is supported by analyst coverage and recent corporate recognitions.
Outlook remains positive with a consensus price target of $212.50, implying 17% upside. Risks include elevated valuation multiples (P/E 37.6) and integration challenges from the UniFirst acquisition. The stock offers growth and income appeal but requires monitoring of execution and market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →
